ICIS Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Technology

Industry

Estimated Revenue & Valuation

  • ICIS's estimated annual revenue is currently $261.9M per year.(i)
  • ICIS's estimated revenue per employee is $282,800

Employee Data

  • ICIS has 926 Employees.(i)
  • ICIS grew their employee count by 50% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.9M60-3%N/AN/A
#2
$1.8M157%N/AN/A
#3
$0.5M50%N/AN/A
#4
$3.3M2335%N/AN/A
#5
$1.9M16-11%N/AN/A
#6
$2.1M1713%N/AN/A
#7
$0.5M5-50%N/AN/A
#8
$0.9M9350%N/AN/A
#9
$1.2M10-17%N/AN/A
#10
$1.2M10N/AN/AN/A
Add Company

ICIS is the global source of Independent Commodity Intelligence Services – connecting data, markets and customers to create a comprehensive trusted view of global commodities markets, enabling smarter business decisions that help optimise the world’s resources.\n\nFor decades, our prices have been the backbone of thousands of transactions around the world.\n\nAt ICIS, we help businesses make strategic decisions, mitigate risk, improve productivity and capitalise on new opportunities. We make some of the world’s most important markets more trusted and predictable by providing data services, thought leadership and decision tools. As a result of our global presence, we deliver targeted connected intelligence to influence thousands of decisions across supply chains every single day. Drawing upon our legacy, we are also in a unique position to leverage big data and analytics as part of RELX, a FTSE20 data and analytics company with over 30,000 experts across 40 countries. With our intelligence, we shape the world by connecting markets to optimise the world’s valuable resources.

keywords:N/A

N/A

Total Funding

926

Number of Employees

$261.9M

Revenue (est)

50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ICIS News

2022-04-17 - ICIs Demonstrate Longer TTNT and OS Over Taxane ...

Investigators report that immune checkpoint inhibitors (ICIs) were had longer time-to-next therapy (TTNT) and longer overall survival (OS)...

2022-04-17 - Evonik's Q1 earnings up 25% on higher selling prices

ICIS market experts share their latest views on the most important factors affecting global energy and chemicals markets. ICIS Chemical Business...

2022-04-17 - INSIGHT: Upstream, energy volatility drives demise of the ...

BARCELONA (ICIS)–A large scale switch from quarterly to monthly contracts is under discussion in Europe, driven by extreme volatility in...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$324.4M9262%N/A
#2
N/A92849%N/A
#3
$327.9M93231%N/A
#4
$462.6M9369%N/A
#5
$134.1M9383%N/A